Convalescent Plasma for Preventing Critical Illness in COVID-19: a Phase 2 Trial and Immune Profile

Convalescent Plasma for Preventing Critical Illness in COVID-19: a Phase 2 Trial and Immune Profile

ABSTRACT The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an unprecedented event requiring frequent adaptation to changing clinical circumstances. Convalescent immune plasma (CIP) is a promising treatment that can be mobilized rapidly in a pandemic...

Full description

Bibliographic Details
Main Authors: Jeffrey M. Sturek, Tania A. Thomas, James D. Gorham, Chelsea A. Sheppard, Allison H. Raymond, Kristen Petros De Guex, William B. Harrington, Andrew J. Barros, Gregory R. Madden, Yosra M. Alkabab, David Y. Lu, Qin Liu, Melinda D. Poulter, Amy J. Mathers, Archana Thakur, Dana L. Schalk, Ewa M. Kubicka, Lawrence G. Lum, Scott K. Heysell
Format: Article
Language:English
Published: American Society for Microbiology 2022-02-01
Series:Microbiology Spectrum
Subjects:
SARS-CoV-2
antibodies
respiratory failure
COVID-19
convalescent plasma
Online Access:https://journals.asm.org/doi/10.1128/spectrum.02560-21

Internet

https://journals.asm.org/doi/10.1128/spectrum.02560-21

Similar Items